Genovese_Kremer_Mar2017
Results – Baseline Demographics and Disease Activity (Study 2) Patient characteristic Placebo n=56 3 mg BID n=55 6 mg BID n=55 ABT-494 12 mg BID n=55 18 mg BID n=55 Age, mean (SD), years 58 (12) 57 (13) 56 (12) 59 (11) 57 (12) Female, n (%) 48 (86) 43 (78) 43 (78) 45 (82) 42 (76) RA duration, mean (SD), years Only 1 prior anti-TNF, n (%) Prior non-anti-TNF agent, n (%) 12.1 (9.0) 11.8 (9.4) 12.3 (10.6) 12.2 (10.2) 10.9 (7.7) 42 (76) 39 (71) 38 (70) 38 (72) 38 (69) 9 (16) 10 (18) 14 (26) 14 (26) 7 (13) HAQ-DI score, mean (SD) 1.6 (0.7) 1.5 (0.7) 1.6 (0.7) 1.6 (0.6) 1.5 (0.6) DAS28(CRP), mean (SD) 5.8 (0.9) 5.7 (0.9) 5.9 (0.9) 5.7 (0.9) 5.8 (1.0) CDAI score, mean (SD) 41 (12) 40 (13) 42 (12) 40 (12) 41 (14) hsCRP >ULN*, n (%) 28 (50) 35 (64) 34 (62) 33 (60) 35 (64) hsCRP, high-sensitivity C-reactive peptide; ULN, upper limit of normal (ULN=5 mg/L). Kremer JM, et al. Arthritis Rheum 2016;68:2867–77.
Results – Primary Endpoint MTX inadequate responders Placebo ABT-494 3 mg ABT-494 6 mg ABT-494 12 mg ABT-494 18 mg ABT-494 24 mg ACR20 rate (%) 46 62 68* 80* 64 76* *P
- Page 1 and 2: Phase 2b Studies of ABT-494, a Sele
- Page 3 and 4: Background and Objectives • ABT-4
- Page 5 and 6: Methods - Study Design • These we
- Page 7: Results - Baseline Demographics and
- Page 11 and 12: Response rate (%) Response rate (%)
- Page 13 and 14: Results - Safety Data Through Week
- Page 15: Conclusions • Selective JAK-1 inh
Results – Baseline Demographics and Disease Activity (Study 2)<br />
Patient characteristic<br />
Placebo<br />
n=56<br />
3 mg BID<br />
n=55<br />
6 mg BID<br />
n=55<br />
ABT-494<br />
12 mg BID<br />
n=55<br />
18 mg BID<br />
n=55<br />
Age, mean (SD), years 58 (12) 57 (13) 56 (12) 59 (11) 57 (12)<br />
Female, n (%) 48 (86) 43 (78) 43 (78) 45 (82) 42 (76)<br />
RA duration, mean (SD),<br />
years<br />
Only 1 prior anti-TNF, n<br />
(%)<br />
Prior non-anti-TNF agent,<br />
n (%)<br />
12.1 (9.0) 11.8 (9.4) 12.3 (10.6) 12.2 (10.2) 10.9 (7.7)<br />
42 (76) 39 (71) 38 (70) 38 (72) 38 (69)<br />
9 (16) 10 (18) 14 (26) 14 (26) 7 (13)<br />
HAQ-DI score, mean (SD) 1.6 (0.7) 1.5 (0.7) 1.6 (0.7) 1.6 (0.6) 1.5 (0.6)<br />
DAS28(CRP), mean (SD) 5.8 (0.9) 5.7 (0.9) 5.9 (0.9) 5.7 (0.9) 5.8 (1.0)<br />
CDAI score, mean (SD) 41 (12) 40 (13) 42 (12) 40 (12) 41 (14)<br />
hsCRP >ULN*, n (%) 28 (50) 35 (64) 34 (62) 33 (60) 35 (64)<br />
hsCRP, high-sensitivity C-reactive peptide; ULN, upper limit of normal (ULN=5 mg/L).<br />
<strong>Kremer</strong> JM, et al. Arthritis Rheum 2016;68:2867–77.
Change language